Discover
TYRA
Tyra Biosciences, Inc.
29.41
2 x 22.72
2 x 38.06
bid
ask
-
2.53
7.92%
2 @ 04:00 PM
29.41 +0.00 (0.00%)
| Ytd | 11.87% | |
| 1y | 202.57% |
29.27
day range
32.30
9.47
52 week range
40.65
| Open | 31.92 | Prev Close | 31.94 | Low | 29.27 | High | 32.30 | Mkt Cap | 1.75B |
| Vol | 741.25K | Avg Vol | 991.59K | EPS | -2.18 | P/E | N/A | Forward P/E | -11.33 |
| Beta | 0.75 | Short Ratio | 10.67 | Inst. Own | 111.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 32.12 | 200-d Avg | 26.92 | 1yr Est | 51.97 |
| Income Statement | |||
| Operating Expenses | 42.00M | ||
| Research and Development Expense | 33.47M | ||
| Selling, General and Administrative Expense | 8.53M | ||
| Operating Income | -42.00M | ||
| Net Income | -39.30M | ||
| Net Income Common Stock | -39.30M | ||
| Net Income Common Stock (USD) | -39.30M | ||
| Consolidated Income | -39.30M | ||
| Earnings per Basic Share | -0.64 | ||
| Earnings per Basic Share (USD) | -0.64 | ||
| Earnings per Diluted Share | -0.64 | ||
| Earning Before Interest & Taxes (EBIT) | -39.30M | ||
| Earning Before Interest & Taxes (USD) | -39.30M | ||
| Weighted Average Shares | 61.75M | ||
| Weighted Average Shares Diluted | 61.75M | ||
| Balance Sheet | |||
| Cash and Equivalents | 85.84M | ||
| Cash and Equivalents (USD) | 85.84M | ||
| Investments | 298.51M | ||
| Investments Current | 298.51M | ||
| Current Assets | 394.61M | ||
| Property, Plant & Equipment Net | 6.66M | ||
| Total Assets | 412.04M | ||
| Debt Current | 488.00K | ||
| Total Debt | 5.70M | ||
| Current Liabilities | 19.26M | ||
| Debt Non-Current | 5.21M | ||
| Total Liabilities | 24.47M | ||
| Accumulated Retained Earnings (Deficit) | -410.56M | ||
| Accumulated Other Comprehensive Income | 107.00K | ||
| Shareholders Equity | 387.58M | ||
| Shareholders Equity (USD) | 387.58M | ||
| Assets Non-Current | 17.43M | ||
| Total Debt (USD) | 5.70M | ||
| Liabilities Non-Current | 5.21M | ||
| Trade and Non-Trade Payables | 3.64M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 138.00K | ||
| Net Cash Flow from Financing | 160.38M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 7.57M | ||
| Capital Expenditure | -88.00K | ||
| Issuance (Purchase) of Equity Shares | 160.38M | ||
| Net Cash Flow from Investing | -120.24M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -120.16M | ||
| Net Cash Flow from Operations | -32.57M | ||
| Share Based Compensation | 7.85M | ||